Amylyx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application (NDA) for AMX0035 for the Treatment of ALS

CAMBRIDGE, Mass.--(BUSINESS WIRE) December 29, 2021 -- Amylyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate (PB) and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news